Forever Labs spins out SuperShot and appoints new chief executive
US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation.
Kevin Virgil has been appointed as the new chief executive of Forever Labs, replacing company co-founder Steven Clausnitzer, who will now lead SuperShot alongside co-founder Mark Katakowski. Both businesses will remain closely aligned, according to the announcement.
Mr Clausnitzer described the transition as “a natural evolution” and said SuperShot had matured to the point that “it deserves dedicated leadership and resources.” The move, he added, “sets the stage” for both companies to thrive independently while maintaining ties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze